Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum

Journal of Neuroscience

Volumn 30, Issue 24, 2010, Pages 8127-8137

  De Chiara, Valentina ^a,c   Angelucci, Francesco ^c   Rossi, Silvia ^a,c   Musella, Alessandra ^a,c   Cavasinni, Francesca ^a,c   Cantarella, Cristina ^a,c   Mataluni, Giorgia ^a,c   Sacchetti, Lucia ^b   Napolitano, Francesco ^d   Castelli, Maura ^a,c   Caltagirone, Carlo ^a,c   Bernardi, Giorgio ^a,c   Maccarrone, Mauro ^c,e   Usiello, Alessandro ^d,f   Centonze, Diego ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d Centro di Ingegneria Genetica e Biotecnologia Avanzate CEINGE   (Italy)

^e UNIVERSITY OF TERAMO   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID 1 RECEPTOR; COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LAVENDUSTIN A; MEMBRANE LIPID; NEUROTROPHIN; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; EMOTION; EXPOSURE; GENE; IN VITRO STUDY; IN VIVO STUDY; LIPID RAFT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REWARD; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRESS;

ANIMALS; BEHAVIOR, ANIMAL; BETA-CYCLODEXTRINS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL; COCAINE; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; GABA AGENTS; HALOPERIDOL; INHIBITORY POSTSYNAPTIC POTENTIALS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PATCH-CLAMP TECHNIQUES; PHENOLS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; REWARD; TETRAHYDROCANNABINOL;

EID: 77953775571     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1683-10.2010     Document Type: Article

References (74)

1. Angelucci F, Ricci V, Pomponi M, Conte G, Mathé AA, Attilio Tonali P, Bria P (2007) Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J Psychopharmacol 21:820-825.
2. Aso E, Ozaita A, Valdizán EM, Ledent C, Pazos A, Maldonado R, Valverde O (2008) BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 105:565-572.
3. Baldelli P, Hernandez-Guijo JM, Carabelli V, Carbone E (2005) Brain-derived neurotrophic factor enhances GABA release probability and nonuniform distribution of N- and P/Q-type channels on release sites of hippocampal inhibitory synapses. J Neurosci 25:3358-3368.
4. 2 receptor responses by an anandamide transport inhibitor. J Neurosci 20:3401-3407.
5. Berchtold NC, Chinn G, Chou M, Kesslak JP, Cotman CW (2005) Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience 133:853-861.
6. Berglind WJ, Whitfield TW Jr, LaLumiere RT, Kalivas PW, McGinty JF (2009) A single intra-PFC infusion of BDNF prevents cocaine-induced alterations in extracellular glutamate within the nucleus accumbens. J Neurosci 29:3715-3719.
7. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggia LM, Self DW, Nestler EJ (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311:864-868.
8. Butovsky E, Juknat A, Goncharov I, Elbaz J, Eilam R, Zangen A, Vogel Z (2005) In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J Neurochem 93:802-811.
9. Calabresi P, Mercuri NB, De Murtas M, Bernardi G (1991) Involvement of GABA systems in feedback regulation of glutamate-and GABA-mediated synaptic potentials in rat neostriatum. J Physiol 440:581-599.
10. Carvalho AL, Caldeira MV, Santos SD, Duarte CB (2008) Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 153 [Suppl 1]:S310-S324.
11. Castrén E (2004) Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol Neurobiol 29:289-302.
12. Centonze D, Battista N, Rossi S, Mercuri NB, Finazzi-Agrò A, Bernardi G, Calabresi P, Maccarrone M (2004) A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology 29: 1488-1497.
13. Centonze D, Rossi S, De Chiara V, Prosperetti C, Battista N, Bernardi G, Mercuri NB, Usiello A, Maccarrone M (2007) Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. Eur J Neurosci 25:1631-1640.
14. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC (2007) High-resolution crystal structure of an engineered human beta2- adrenergic G protein-coupled receptor. Science 318:1258-1265.
15. Dawson NM, Hamid EH, Egan MF, Meredith GE (2001) Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 39:70-81.
16. De Chiara V, Errico F, Musella A, Rossi S, Mataluni G, Sacchetti L, Siracusano A, Castelli M, Cavasinni F, Bernardi G, Usiello A, Centonze D (2010) Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum. Neuropsychopharmacology 35:374-387.
17. D'Souza DC, Pittman B, Perry E, Simen A (2009) Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 202:569-578.
18. Eisch AJ, Bolaños CA, de Wit J, Simonak RD, Pudiak CM, Barrot M, Verhaagen J, Nestler EJ (2003) Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry 54:994-1005.
19. El Rawas R, Thiriet N, Lardeux V, Jaber M, Solinas M (2009) Environmental enrichment decreases the rewarding but not the activating effects of heroin. Psychopharmacology 203:561-570.
20. Favilla C, Abel T, Kelly MP (2008) Chronic Galphas signaling in the striatum increases anxiety-related behaviors independent of developmental effects. J Neurosci 28:13952-13956.
21. Frerking M, Malenka RC, Nicoll RA (1998) Brain-derived neurotrophic factor (BDNF) modulates inhibitory, but not excitatory, transmission in the CA1 region of the hippocampus. J Neurophysiol 80:3383-3386. (Pubitemid 29029266)
22. Fumagalli F, Di Pasquale L, Caffino L, Racagni G, Riva MA (2007) Repeated exposure to cocaine differently modulates BDNF mRNA and protein levels in rat striatum and prefrontal cortex. Eur J Neurosci 26:2756-2763.
23. Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M (2008) Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 14:2279-2288.
24. Gerdeman GL, Ronesi J, Lovinger DM (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5:446-451.
25. Gerdeman GL, Partridge JG, Lupica CR, Lovinger DM (2003) It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci 26:184-192.
26. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
27. Hajnal A, Smith GP, Norgren R (2004) Oral sucrose stimulation increases accumbens dopamine in the rat. Am J Physiol Regul Integr Comp Physiol 286:R31-R37.
28. Hanzal-Bayer MF, Hancock JF (2007) Lipid rafts and membrane traffic. FEBS Lett 581:2098-2104.
29. Hashimoto K (2007) BDNF variant linked to anxiety-related behaviors. Bioessays 29:116-119.
30. Hennigan A, O'Callaghan RM, Kelly AM (2007) Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. Biochem Soc Trans 35:424-427.
31. Horder J, Cowen PJ, Di Simplicio M, Browning M, Harmer CJ (2009) Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology 205:85-91.
32. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 [Suppl 1]:345-358.
33. Huang Y, Yasuda H, Sarihi A, Tsumoto T (2008) Roles of endocannabinoids in heterosynaptic long-term depression of excitatory synaptic transmission in visual cortex of young mice. J Neurosci 28:7074-7083.
34. Jeanblanc J, He DY, McGough NN, Logrip ML, Phamluong K, Janak PH, Ron D (2006) The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J Neurosci 26:1457-1464.
35. Johnson RA, Rhodes JS, Jeffrey SL, Garland T Jr, Mitchell GS (2003) Hippocampal brain-derived neurotrophic factor but not neurotrophin-3 increases more in mice selected for increased voluntary wheel running. Neuroscience 121:1-7.
36. Juhasz G, Chase D, Pegg E, Downey D, Toth ZG, Stones K, Platt H, Mekli K, Payton A, Elliott R, Anderson IM, Deakin JF (2009) CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 34:2019-2027.
37. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B (2004) Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 19:1691-1698.
38. Kim KS, Lee KW, Baek IS, Lim CM, Krishnan V, Lee JK, Nestler EJ, Han PL (2008) Adenylyl cyclase-5 activity in the nucleus accumbens regulates anxiety-related behavior. J Neurochem 107:105-115.
39. Küppers E, Beyer C (2001) Dopamine regulates brain-derived neurotrophic factor (BDNF) expression in cultured embryonic mouse striatal cells. Neuroreport 12:1175-1179. (Pubitemid 32374739)
40. Li YX, Xu Y, Ju D, Lester HA, Davidson N, Schuman EM (1998) Expression of a dominant negative TrkB receptor, T1, reveals a requirement for pre-synaptic signaling in BDNF-induced synaptic potentiation in cultured hippocampal neurons. Proc Natl Acad Sci U S A 95:10884-10889.
41. Lu B, Pang PT, Woo NH (2005) The yin and yang of neurotrophin action. Nat Rev Neurosci 6:603-614.
42. Lucero HA, Robbins PW (2004) Lipid rafts-protein association and the regulation of protein activity. Arch Biochem Biophys 426:208-224.
43. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, Gasperi V, Prosperetti C, Bernardi G, Finazzi-Agrò A, Cravatt BF, Centonze D (2008) Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11:152-159.
44. Maccarrone M, De Chiara V, Gasperi V, Viscomi MT, Rossi S, Oddi S, Molinari M, Musella A, Finazzi-Agrò A, Centonze D (2009) Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum. J Neurochem 109:371-381.
45. Maison P, Walker DJ, Walsh FS, Williams G, Doherty P (2009) BDNF regulates neuronal sensitivity to endocannabinoids. Neurosci Lett 467:90-94.
46. Mark GP, Blander DS, Hoebel BG (1991) A conditioned stimulus decreases extracellular dopamine in the nucleus accumbens after the development of a learned taste aversion. Brain Res 551:308-310.
47. Martínez-Orgado J, Fernández-López D, Lizasoain I, Romero J (2007) The seek of neuroprotection: introducing cannabinoids. Recent Pat CNS Drug Discov 2:131-139.
48. Martinowich K, Manji H, Lu B (2007) New insights into BDNF function in depression and anxiety. Nat Neurosci 10:1089-1093.
49. Mathew SJ, Ho S (2006) Etiology and neurobiology of social anxiety disorder. J Clin Psychiatry 67 [Suppl 12]:9-13. (Pubitemid 44836355)
50. McGinty JF, Whitfield TW Jr, Berglind WJ (2010) Brain-derived neurotrophic factor and cocaine addiction. Brain Res 1314:183-193.
51. Moreira FA, Grieb M, Lutz B (2009) Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23:133-144.
52. + in cultured cerebellar neurons. J Neurosci Res 66:96-108.
53. Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I (1992) Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. FEBS Lett 313:138-142.
54. Oliff HS, Berchtold NC, Isackson P, Cotman CW (1998) Exercise-induced regulation of brain-derived neurotrophic factor (BDNF) transcripts in the rat hippocampus. Brain Res Mol Brain Res 61:147-153.
55. Pillai A, Terry AV Jr, Mahadik SP (2006) Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 82:95-106.
56. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A (2009) Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12:1152-1158.
57. Reiman EM, Raichle ME, Robins E, Mintun MA, Fusselman MJ, Fox PT, Price JL, Hackman KA (1989) Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry 46:493-500.
58. Rogan MT, Leon KS, Perez DL, Kandel ER (2005) Distinct neural signatures for safety and danger in the amygdala and striatum of the mouse. Neuron 46:309-320.
59. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK (2007) GPCR engineering yields high-resolution structural insights into beta2- adrenergic receptor function. Science 318:1266-1273.
60. Rossi S, De Chiara V, Musella A, Kusayanagi H, Mataluni G, Bernardi G, Usiello A, Centonze D (2008) Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J Neurosci 28:7284-7292.
61. Saylor AJ, McGinty JF (2008) Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice. Genes Brain Behav 7:906-914.
62. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioural models of depression. J Neurosci 22:3251-3261. (Pubitemid 35379212)
63. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997) Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56:131-137.
64. Suzuki S, Kiyosue K, Hazama S, Ogura A, Kashihara M, Hara T, Koshimizu H, Kojima M (2007) Brain-derived neurotrophic factor regulates cholesterol metabolism for synapse development. J Neurosci 27:6417-6427.
65. Teegarden SL, Nestler EJ, Bale TL (2008) Delta FosB-mediated alterations in dopamine signaling are normalized by a palatable high-fat diet. Biol Psychiatry 64:941-950.
66. Wardle RA, Poo MM (2003) Brain-derived neurotrophic factor modulation of GABAergic synapses by postsynaptic regulation of chloride transport. J Neurosci 23:8722-8732.
67. Waterhouse EG, Xu B (2009) New insights into the role of brain-derived neurotrophic factor in synaptic plasticity. Mol Cell Neurosci 42:81-89.
68. Williams SN, Undieh AS (2009) Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression. Neuroreport 20:606-610.
69. Williams SN, Undieh AS (2010) Brain-derived neurotrophic factor signaling modulates cocaine induction of reward-associated ultrasonic vocalization in rats. J Pharmacol Exp Ther 332:463-468.
70. Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B (2005) Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 8:1069-1077.
71. Yin HH, Lovinger DM (2006) Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc Natl Acad Sci U S A 103:8251-8256.
72. Yoo HK, Kim MJ, Kim SJ, Sung YH, Sim ME, Lee YS, Song SY, Kee BS, Lyoo IK (2005) Putaminal gray matter volume decrease in panic disorder: an optimized voxel-based morphometry study. Eur J Neurosci 22:2089-2094.
73. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, Dlaboga D, Jin SL, Conti M, O'Donnell JM (2008) Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B PDE4B. Neuropsychopharmacology 33:1611-1623.
74. Zhang X, Andren PE, Svenningsson P (2006) Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Res 1095:207-210.